
Issue 2026-10 · October 2026
Four developments that shaped October
- Women's & reproductive health: CCHF in pregnancy linked to 28.8% maternal death and 57.4% fetal loss in meta-analysis
- Oncology: Felzartamab plus lenalidomide-dexamethasone extends progression-free survival in relapsed or refractory multiple myeloma
- Neurology: JUVMO approved for Parkinson’s disease in adults
- Infectious disease: Long-acting HIV injections match oral pills for viral suppression in African adults with adherence challenges
